These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis. Kheir MM, Baraka OZ, el-Tom IA, Mukhtar MM, Homieda MM. East Mediterr Health J; 2000; 6(5-6):926-31. PubMed ID: 12197350 [Abstract] [Full Text] [Related]
27. A survey of Schistosoma mansoni induced kidney disease in children in an endemic area of Machakos District, Kenya. Johansen MV, Simonsen PE, Butterworth AE, Ouma JH, Mbugua GG, Sturrock RF, Orinda DA, Christensen NO. Acta Trop; 1994 Oct; 58(1):21-8. PubMed ID: 7863851 [Abstract] [Full Text] [Related]
29. Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of Schistosoma mansoni infections. Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PNM, Montgomery SP, Secor WE. PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006033. PubMed ID: 29059190 [Abstract] [Full Text] [Related]
30. The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda. Namwanje H, Kabatereine NB, Olsen A. Parasitology; 2011 Oct; 138(12):1586-92. PubMed ID: 21349218 [Abstract] [Full Text] [Related]
33. Comparing the performance of circulating cathodic antigen and Kato-Katz techniques in evaluating Schistosoma mansoni infection in areas with low prevalence in selected counties of Kenya: a cross-sectional study. Okoyo C, Simiyu E, Njenga SM, Mwandawiro C. BMC Public Health; 2018 Apr 11; 18(1):478. PubMed ID: 29642875 [Abstract] [Full Text] [Related]
35. Reduction in prevalence, intensity of infection and morbidity due to Schistosoma mansoni infection in a community following treatment with praziquantel. Sukwa TY, Bulsara MK, Wurapa FK. J Trop Med Hyg; 1987 Aug 11; 90(4):205-11. PubMed ID: 3116277 [Abstract] [Full Text] [Related]
36. Morbidity associated with schistosomiasis before and after treatment in young children in Rusinga Island, western Kenya. Davis SM, Wiegand RE, Mulama F, Kareko EI, Harris R, Ochola E, Samuels AM, Rawago F, Mwinzi PM, Fox LM, Odiere MR, Won KY. Am J Trop Med Hyg; 2015 May 11; 92(5):952-8. PubMed ID: 25758651 [Abstract] [Full Text] [Related]
37. The impact of single versus mixed Schistosoma haematobium and S. mansoni infections on morbidity profiles amongst school-children in Taveta, Kenya. Gouvras AN, Kariuki C, Koukounari A, Norton AJ, Lange CN, Ireri E, Fenwick A, Mkoji GM, Webster JP. Acta Trop; 2013 Nov 11; 128(2):309-17. PubMed ID: 23313322 [Abstract] [Full Text] [Related]
39. A comparative study of the nutritional status, parasitic infections and health of male roadworkers in four areas of Kenya. Latham MC, Stephenson LS, Hall A, Wolgemuth JC, Elliott TC, Crompton DW. Trans R Soc Trop Med Hyg; 1982 Nov 11; 76(6):734-40. PubMed ID: 7164140 [Abstract] [Full Text] [Related]
40. Effect of targeted mass treatment on intensity of infection and morbidity in schistosomiasis mansoni: seven-year follow-up of a community in Machakos, Kenya. DeStigter KV, King CH, Keating CE, Ouma JH, Siongok TK, Mahmoud AA. Trans Assoc Am Physicians; 1989 Nov 11; 102():209-12. PubMed ID: 2517855 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]